MedTrace Logo

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

NCT04019262 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-06-18

No results posted yet for this study

Summary

This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma.

Conditions

Interventions

RADIATION

Radiation Therapy

Radiation

DRUG

Temozolomide Oral Product

Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)

Sponsors & Collaborators

  • John Flickinger

    lead OTHER

Principal Investigators

  • John Flickinger, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04019262 on ClinicalTrials.gov